The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis.

Brussels (Belgium), 8th December 2022– UCB, a global biopharmaceutical company, announced yesterday that The Lancet has published two articles detailing 24-week results from the Phase 3 BE OPTIMAL study and 16-week results from the Phase 3 BE COMPLETE study, evaluating the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and tumour necrosis factor inhibitor inadequate responders (TNFi-IR), respectively. [i] , [ii] “Publication of two articles in tandem in The Lancet, one of the world’s most prestigious peer-reviewed journals...